(Q34950559)

5 August 2017

1 reference

title

Hepatic disease in injection drug users (English)

1 reference

5 August 2017

Brent D Lemberg

1

1 reference

PubMed ID

12371121

5 August 2017

Thomas A Shaw-Stiffel

series ordinal

2

1 reference

5 August 2017

1 September 2002

1 reference

Infectious Disease Clinics of North America

5 August 2017

1 reference

5 August 2017

16

1 reference

5 August 2017

3

1 reference

5 August 2017

667-679

1 reference

The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Multiple modes of hepatitis A virus transmission among methamphetamine users.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

1 reference

7 January 2021

Epidemiology of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Distribution of infecting hepatitis C virus genotypes in end-stage liver disease patients at a large American transplantation center

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Treatment of chronic hepatitis D with interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

1 reference

7 January 2021

Hepatitis C virus in intravenous drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

1 reference

7 January 2021

Treatment of hepatitis C infection in injection drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Correlates of hepatitis C virus infections among injection drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Sharing of drug preparation equipment as a risk factor for hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Managing chronic hepatitis C acquired through intravenous drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Hepatitis G virus infection: a work in progress

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2802%2900014-4

7 January 2021

10.1016/S0891-5520(02)00014-4

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12371121